Antimalarial Effects of Human Immunodeficiency Virus Type 1 Protease Inhibitors Differ from Those of the Aspartic Protease Inhibitor Pepstatin
Authors:
Open Access
- 1 June 2006
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 50 (6) , 2207-2209
Abstract
Human immunodeficiency virus type 1 protease inhibitors (HIVPIs) and pepstatin are aspartic protease inhibitors with antimalarial activity. In contrast to pepstatin, HIVPIs were not synergistic with a cysteine protease inhibitor or more active against parasites with the cysteine protease falcipain-2 knocked out than against wild-type parasites. As with pepstatin, HIVPIs were equally active against wild-type parasites and against parasites with the food vacuole plasmepsin aspartic proteases knocked out. The antimalarial mechanism of HIVPIs differs from that of pepstatin.Keywords
This publication has 15 references indexed in Scilit:
- Characterization of plasmepsin V, a membrane-bound aspartic protease homolog in the endoplasmic reticulum of Plasmodium falciparumMolecular and Biochemical Parasitology, 2005
- Antimalarial Effects of HIV Proteinase Inhibitors: Common Compounds but Structurally Distinct EnzymesThe Journal of Infectious Diseases, 2005
- Antimalarial Activity of Human Immunodeficiency Virus Type 1 Protease InhibitorsAntimicrobial Agents and Chemotherapy, 2005
- Aspartic Proteases ofPlasmodium falciparumas the Target of HIV‐1 Protease InhibitorsThe Journal of Infectious Diseases, 2005
- Cysteine proteases of malaria parasitesInternational Journal for Parasitology, 2004
- Antiretrovirals as Antimalarial AgentsThe Journal of Infectious Diseases, 2004
- Data-Mining Approaches Reveal Hidden Families of Proteases in the Genome of Malaria ParasiteGenome Research, 2003
- Aspartic Peptidase Inhibitors: Implications in Drug DevelopmentCritical Reviews in Biochemistry and Molecular Biology, 2003
- Comparison of Efficacies of Cysteine Protease Inhibitors against Five Strains of Plasmodium falciparumAntimicrobial Agents and Chemotherapy, 2001
- Plasmodium falciparum: Differential Sensitivity In Vitro to E‐64 (Cysteine Protease Inhibitor) and Pepstatin A (Aspartyl Protease Inhibitor)The Journal of Protozoology, 1992